Conversely, EVI2B, a single‐pass type I transmembrane glycoprotein, was reportedly involved in tumor immunity, since the cytotoxic activity of CD8+ T cells was intensified in melanoma patients with its higher expression [29]. This evidence concerns the gene CD8A and melanoma.